Chromocell Therapeutics Co. (NYSE:CHRO) Short Interest Down 28.1% in May

Chromocell Therapeutics Co. (NYSE:CHRO) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 125,900 shares, a drop of 28.1% from the May 15th total of 175,100 shares. Based on an average daily volume of 672,100 shares, the short-interest ratio is presently 0.2 days. Approximately 14.2% of the shares of the company are sold short.

Chromocell Therapeutics Stock Down 4.6%

CHRO stock opened at $1.19 on Friday. The company has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.34. The company has a market capitalization of $7.85 million, a P/E ratio of -0.96 and a beta of 3.22. Chromocell Therapeutics has a fifty-two week low of $0.45 and a fifty-two week high of $3.80.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.